Hexima Limited is a biotechnology company actively engaged in the research and development of plant-derived molecules for use in human health and agriculture.


For information relating to investor updates, financial information, share trading and presentations click the link below.


Hexima is developing technology for use in transgenic plants to prevent damage by fungal pathogens and insect pests and for the treatment of fungal infections and non-melanoma skin cancer in humans.

Updated: Upcoming CEO Presentations

Shareholders are invited to attend a presentation by Hexima CEO Dr Nicole van der Weerden. To view a copy of the presentation click here.

Upcoming Event: Tuesday 25th July at 11.30am at Lvl 38, 88 Phillip Street Sydney (offices of Bell Potter).

Hexima Shareholder Update and Share Trading

Hexima is pleased to advise that it has completed a pivotal GLP repeat-dose dermal irritation study in minipigs for HPX124 which should provide sufficient pre-clinical animal toxicology data to support a first-in-human clinical trial for HXP124 as a treatment of onychomycosis. Further details are provided in the presentation.

Hexima Rights Issue Completed

Dear Shareholders I am pleased to inform you that the Hexima Rights Issue successfully closed last week with an overall take-up through entitlements and oversubscriptions of 65.4%.  This result was very encouraging and Hexima is grateful to all shareholders who...

Extension of Hexima’s rights issue offer

Hexima Limited ACN 079 319 314 (Company) wishes to advise shareholders that it is extending the invitation for shareholders to participate in the rights issue of 6 new shares for every 10 shares which shareholders held on the relevant record date (Offer), under the...

External Links

Take a look at these useful links to learn more about our industry.